Drugs & Targets FDA grants priority review for sevabertinib in HER2-mutant NSCLC May 30, 2025Vol.51 No.21
Drugs & Targets Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer May 30, 2025Vol.51 No.21
Regulatory News ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session May 23, 2025Vol.51 No.20By Jacquelyn Cobb
Cancer Policy FDA Commissioner Makary holds roundtable discussion on harms of talc May 23, 2025Vol.51 No.20By Claire Marie Porter
Cancer Policy Prasad’s stricter FDA policy for COVID-19 vaccines could limit future access May 23, 2025Vol.51 No.20By Claire Marie Porter
Drugs & Targets FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer May 23, 2025Vol.51 No.20
Drugs & Targets FDA approves Emrelis for previously treated, advanced NSCLC with high c-Met protein overexpression May 16, 2025Vol.51 No.19
Drugs & Targets FDA approves Zynyz as first-line treatment for advanced anal cancer May 16, 2025Vol.51 No.19
